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We have previously reported that human cytomegalovirus (HCMV) infection induces large-scale changes to
host cell glycolytic, nucleic acid, and phospholipid metabolism. Here we explore the viral mechanisms involved
in fatty acid biosynthetic activation. Our results indicate that HCMV targets ACC1, the rate-limiting enzyme
of fatty acid biosynthesis, through multiple mechanisms. HCMV infection was found to activate ACC1 expres-
sion, increasing the abundance of both ACC1 mRNA and protein. Viral gene expression but not viral DNA
replication was found to be necessary for HCMV-mediated induction of ACC1 levels. HCMV infection was also
found to increase the proteolytic processing of SREBP-2, a transcription factor whose proteolytic cleavage is
known to activate a variety of phospholipid metabolic genes. Processing of SREBP-2 was found to be dependent
on mTOR activity; pharmaceutical inhibition of mTOR blocked HCMV-induced SREBP-2 processing and
prevented the induction of fatty acid biosynthesis and ACC1 expression. Independent of the increases in ACC1
expression, HCMV infection also induced ACC1’s enzymatic activity. Inhibition of ACC1 through either RNA
interference (RNAi) or inhibitor treatment was found to attenuate HCMV replication, and HCMV replication
was sensitive to ACC1 inhibition even at the later stages of infection, suggesting a late role for fatty acid
biosynthesis during HCMV replication. These findings indicate that HCMV infection actively modulates
numerous functional aspects of a key metabolic regulatory enzyme that is important for high-titer viral
replication.
For decades, numerous reports have indicated that infection
with a wide variety of evolutionarily divergent viruses results in
a general activation of host cell metabolism (7, 15, 16, 26, 29,
39, 42). This metabolic activation can be therapeutically useful;
for example, increased or divergent nucleotide metabolism is
often clinically targeted to treat various viral infections, such as
hepatitis B virus, HIV, human cytomegalovirus (HCMV), and
herpes simplex virus (3, 13, 18, 28). Despite the successes of
these antiviral strategies, relatively little is known about the
specific metabolic activities induced by viral infection and the
mechanisms responsible for their activation. Given the viral
reliance on the host cell metabolic network for the production
of viral progeny, elucidating the mechanisms of viral metabolic
manipulation will likely highlight novel avenues for therapeutic
development.
HCMV is a widespread opportunistic pathogen that can
cause severe disease in various immunosuppressed popula-
tions, including the elderly, cancer patients receiving immuno-
suppressive chemotherapy, transplant recipients, and AIDS
patients (17, 38). Additionally, congenital HCMV infection
occurs in 1 to 2% of all live births (3) and can result in multiple
organ system abnormalities, with central nervous system dam-
age occurring in the majority of symptomatic newborns
(11, 38).
HCMV is a large, double-stranded DNA virus that contains
an 240-kb genome encoding over 200 open reading frames
(ORFs). The HCMV genome is encased within a protein cap-
sid which itself is surrounded by a protein layer named the
tegument. The capsid and tegument are then enclosed within a
phospholipid envelope containing glycoproteins.
We have previously found that infection with HCMV in-
duces numerous changes to the host cell metabolic network
(34, 35). Specifically, HCMV induces much of central carbon
metabolism, including glycolysis and the tricarboxylic acid
(TCA) cycle, but reduces the activity of the pentose-phosphate
pathway (35). In addition, HCMV infection results in notable
increases in phospholipid biosynthesis, which when inhibited
results in attenuated HCMV replication (35).
Acetyl-coenzyme A (CoA) carboxylase (ACC) catalyzes the
first committed step in fatty acid biosynthesis, the carboxyla-
tion of acetyl-CoA to form malonyl-CoA. There are two major
isoforms of ACC, ACC1 (265 kDa) and ACC2 (280 kDa),
which are encoded by two distinct genes (1, 2). ACC1 is ubiq-
uitously expressed, whereas ACC2 is expressed primarily in
strongly fatty acid-oxidative tissues, such as skeletal and heart
muscle (reviewed in reference 33). ACC1 is heavily regulated
by diverse upstream signals. For example, its activity is inhib-
ited by signal transduction cascades that result in phosphory-
lation at ser79 (reviewed in reference 9).
Here, we have begun to analyze the mechanisms responsible
for HCMV-induced activation of fatty acid biosynthesis. We
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find that HCMV infection increases the expression and specific
activity of ACC1. Taken together, our data suggest that
HCMV infection targets a cellular metabolic enzyme whose
activity is important for viral replication. We propose that the
interplay between viruses and the host cell metabolic machin-
ery is a fundamental host-pathogen interaction whose contin-
ued elucidation may prove fertile ground for novel therapeutic
development.
MATERIALS AND METHODS
Biological reagents and cell culture. MRC-5 fibroblasts were maintained in
Dulbecco’s modified Eagle medium (DMEM) (Gibco) containing 10% fetal
bovine serum and 4.5 g liter1 glucose. Prior to infection, fibroblasts were grown
to confluence, resulting in 3.2  104 cells per cm2. In all infections, viral inocula
were added to cells for a 2-h adsorption period and then aspirated. In experi-
ments utilizing UV-irradiated virus, the viral inocula were exposed to 254 nm
light at various doses (indicated in Fig. 3) in a Stratalinker UV cross-linker 2400
prior to infection. In the event of serum starvation, serum-containing medium
was removed and serum-free medium added. Cells were then maintained in
serum-free DMEM for 24 h prior to infection. For experiments involving mea-
surement of viral titers via plaque assay, unbound virus was inactivated through
a sodium citrate wash (40 mM sodium citrate, 10 mM KCl, and 135 mM NaCl,
pH 3.0) followed by a DMEM wash immediately following viral adsorption.
Unless indicated otherwise, BADwt was the strain utilized in all studies. BADwt
was derived from a bacterial artificial chromosome (BAC) clone of the AD169
laboratory strain of HCMV (52). A green fluorescent protein (GFP)-expressing
virus (HCMV-GFP), BADsubUL21.5, expresses GFP under the control of the
simian virus 40 (SV40) early promoter and replicates to similar titers and with
the same growth kinetics as wild-type virus (49).
Antibodies used were specific for ACC (Cell Signaling), phospho-ACC (ser79)
(Cell Signaling), -tubulin (Epitomics), polyclonal SREBP-2 (Abcam), mono-
clonal SREBP-2 (MBL), and ATP-dependent citrate lyase (ACL) (Cell Signal-
ing). Monoclonal antibodies to the following viral proteins were also utilized: IE2
(T. Shenk laboratory, unpublished), UL26 (36), and pp65 (37).
Analysis of RNA and protein. RNA accumulation was assayed by quantitative
real-time PCR. RNA was prepared using Trizol (Invitrogen) as recommended by
the manufacturer. cDNA synthesis was performed utilizing SuperScript First-
Strand (Invitrogen) reagents with random hexamers as per the manufacturer’s
protocol. Quantitative PCR (qPCR) was performed using Fast SYBR green PCR
master mix, 7500 Fast real-time PCR system sequence detection, and 7500
software version 2.0.1 (Applied Biosystems) following the manufacturer’s in-
structions. Transcripts were quantified with specific primer pairs as follows: the
ACC1 transcript with 5 TTAACAGCTGTGGAGTCTGGCTGT 3 and 5 AA
CACTCGATGGAGTTTCTCGCCT 3, the ACC2 transcript with 5 GGTGCT
TATTGCCAACAACGGGAT 3 and 5 TCTTGATGTACTCTGCGTTG
GCCT 3, the ACL transcript with 5 TGACAGCACCATGGAGACCATGAA
3 and 5 TTGCCAATCTTAAAGCACCCAGGC 3, the fatty acid synthase
(FAS) transcript with 5 AGAACTTGCAGGAGTTCTGGGACA 3 and 5
TCCGAAGAAGGAGGCATCAAACCT 3, and the glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) transcript, used for normalization, with 5 CA
TGTTCGTCATGGGTGTGAACCA 3 and ATGGCATGGACTGTGGT-
CATGAGT 3. Quantitative PCR was performed using the CT (threshold
cycle) method, with GAPDH as a control.
Protein accumulation was assayed by Western blotting. Cells were washed with
phosphate-buffered saline (PBS), scraped, and solubilized in disruption buffer
containing 50 mM Tris (pH 7.0), 2% SDS, 5% 2-mercaptoethanol, and 2.75%
sucrose. Resulting extracts were sonicated, boiled for 5 min, and centrifuged
briefly at 14,000  g to pellet insoluble material. Extracts were then subjected to
electrophoresis in an SDS-8% or -10% polyacrylamide gel and transferred to a
nitrocellulose sheet. Blots were then stained with Ponceau S to ensure equivalent
protein loading and transfer, blocked by incubation in 5% milk, and reacted with
primary and subsequently secondary antibodies. Protein bands were visualized
through enhanced chemifluorescent detection, according to the instructions of
the manufacturer (Amersham), and signals were obtained with a Typhoon 9410
phosphorimager. For SREBP-2 Western analysis, protein bands were visualized
using an ECL system (Pierce) and scientific imaging film (Kodak). In certain
instances, the brightness and contrast of the resulting images were adjusted in
Microsoft PowerPoint to improve image clarity. All such processing was applied
uniformly to the entire image.
For analysis of the phospho-ACC (ser79) antibody, fibroblasts were scraped in
phosphatase buffer containing 50 mM Tris-HCl, pH 7.9, 100 mM NaCl, 10 mM
MgCl2, 1 mM dithiothreitol, and 1% Triton X-100 with or without phosphatase
inhibitors (10 mM NaF, 100 M sodium orthovanadate). Cells were then soni-
cated and the resulting extracts incubated at 37°C with or without 200 units of
calf intestinal phosphatase (CIP) (New England BioLabs) for 1 h. The sample
volume was then brought up to 250 l with disruption buffer, and samples were
processed for Western analysis as described above.
For immunofluorescence, fibroblasts were grown on glass coverslips. At vari-
ous times postinfection, cells were washed once with PBS, fixed with 2% para-
formaldehyde in PBS for 15 min, and washed three times with PBS. Cells were
subsequently blocked by overnight incubation in PBS containing 2% bovine
serum albumin (BSA), 5% goat serum, 5% human serum, and 0.3% Triton
X-100. We found that blocking with human serum is essential to prevent arti-
factual staining of the viral assembly zone. Initial experiments were performed
without human serum but containing goat serum in the blocking solution, which
led to assembly zone staining (see Fig. S1 in the supplemental material). This
artifactual staining was likely the result of HCMV-encoded Fc receptor binding
nonspecifically to antibody (4, 10). Cells were incubated with primary antibody
diluted in PBS plus 0.3% Triton X-100 overnight, washed three times in PBS,
incubated with fluorochrome-conjugated secondary antibody, and washed again
three times with PBS. Coverslips were mounted in SlowFade Gold antifade
reagent with 4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes). Confo-
cal images were captured with an FV1000 Olympus laser scanning confocal
microscope. For Fig. 6, all images were captured under identical confocal set-
tings.
RNAi assay. The following small interfering RNA (siRNA) duplexes were
obtained from Dharmacon Research. For ACC1 targeting, 5 CAAUGGCAU
UGCAGCAGUG 3 and its complementary sequence were utilized. For a non-
protein-targeting control, 5 CGUAAGCGACAUACUUACAUU 3 and its
complement were utilized. MRC-5 fibroblasts at 30% confluence were trans-
fected with 75 nM RNA interference (RNAi) duplex using Oligofectamine (In-
vitrogen) as per the manufacturer’s instructions.
Pharmaceuticals. 5-Tetradecyloxy-2-furoic acid (TOFA) (Cayman) was main-
tained as a 5 mg ml1 stock in dimethyl sulfoxide (DMSO). Potential toxicity of
TOFA was analyzed by a Live/Dead assay (MGT) according to the manufactur-
er’s protocol. Phosphonoacetic acid (PAA) (MP Biomedicals) was maintained as
a 20 mg ml1 stock in water. Torin1 was maintained as a 250 M stock in DMSO.
Measurement of acetyl-CoA carboxylase activity. ACC activity in fibroblasts
was evaluated by measuring the relative amount of malonyl-CoA produced
during a given time via liquid chromatography-tandem mass spectrometry (LC–
MS-MS). The ACC assays were conducted largely as reported previously (30),
with the exception that malonyl-CoA production was detected by mass spectrom-
etry instead of fixed radioactivity. For the ACC assay, fibroblasts were plated in
15-cm dishes at 5  106 cells dish1. Cells were scraped in PBS, pelleted by
low-speed centrifugation, and solubilized in 200 l reaction buffer containing 20
mM HEPES, pH 7.4, 10 mM MgCl2, 10 mM sodium citrate, 5 mM sodium
bicarbonate, 0.5% DMSO, and 0.038% fatty acid-free BSA. To lyse cells, sam-
ples were frozen at 80°C and thawed at 37°C a total of three times. Samples
were then centrifuged at 13,000  g for 10 min, and the supernatant was
preincubated at 37°C for 10 min. To begin the reaction, 3.75 mM ATP and 9.3
M acetyl-CoA (final concentrations) were simultaneously added to the sample,
and the sample was incubated at 37°C. Twenty-microliter aliquots were then
taken at 30, 60, and 120 s postincubation. Sample aliquots were quenched with
120 l 80% methanol (MeOH), centrifuged at 13,000  g for 5 min, and analyzed
via LC–MS-MS. The LC–MS-MS conditions were as follows. LC separation was
coupled by negative-mode electrospray ionization (ESI) to a triple-quadrupole
mass spectrometer operating in multiple reaction monitoring mode. The LC
method was reverse-phase chromatography using a Synergi 4-m Hydro-RP
80-Å column coupled to a SecurityGuard guard cartridge (Phenomenex). LC
solvents were as follows: solvent A, 100% methanol; solvent B, 10 mM tributyl-
amine and 15 mM acetic acid in 97:3 water-methanol. The LC method param-
eters were as follows (t in minutes): t  0, 15% A; t  0.5, 15% A; t  4, 97%
A; t  5, 97% A; t  5.1, 15% A; t  7, 15% A. For LC, we used an LC-20 AD
high-pressure liquid chromatography (HPLC) system (Shimadzu) with an au-
tosampler temperature of 4°C, oven temperature of 40°C, and injection volume
of 10 l. For MS, we used a TSQ Quantum Ultra triple-quadrupole mass
spectrometer (Thermo Fisher Scientific). The mass spectrometer parameters for
malonyl-CoA in negative mode were a 12C parent mass of 852 m/z, a collision cell
energy of 24 eV, and a product mass of 808 m/z.
The resulting ACC activity data were fit to a single exponential curve of
product formation, P(t)  Pmax(1ekt). Initial velocities of product production,
k  Pmax, were plotted as ACC activity.
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Measurement of fatty acid biosynthesis. Fatty acid biosynthesis was evaluated
largely as indicated previously (21). Briefly, fatty acid biosynthesis in fibroblasts
was assayed by measuring the incorporation of [1-14C]acetic acid (NEN Radio-
chemicals) into cellular lipids. Fibroblasts were plated in 12-well plates at 1.2 
105 cells well1. To begin the assay, 500 l of DMEM containing 1 Ci of 56.2
mCi mmol1 [1-14C]acetic acid was added to each well, and cells were incubated
at 37°C for 2 h. After incubation, cells were washed with PBS and dissolved in 0.5
ml of 0.2 M KOH. Samples were then saponified by the addition of 0.3 ml of 50%
KOH and 2.0 ml of ethanol, followed by a 2-h incubation at 75°C and then an
overnight incubation at room temperature. After saponification, the samples
were extracted two times with 4.5 ml of hexane. The hexane-containing fractions
were discarded, and the remaining fractions containing fatty acids were acidified
to pH 	2 by the addition of 0.5 ml 12 M HCl. After acidification, the samples
were extracted one time with 4.5 ml hexane. The organic fractions were dried
under N2, resuspended in 50 l of 1:1 chloroform-hexane, dissolved in 1 ml of
Ecoscint O liquid scintillation fluid, and assessed for radioactivity using a Beck-
man LS6500 liquid scintillation counter.
RESULTS
Impact of HCMV infection on fatty acid biosynthesis and
acetyl-CoA carboxylase activity. We have previously utilized
LC–MS-MS to globally measure the impact of HCMV infec-
tion at 48 h postinfection (hpi), a time of robust viral DNA
synthesis. We found that HCMV infection induced phospho-
lipid biosynthesis, increasing the production of both phospho-
lipid fatty acids and glycerol head groups (35). To more thor-
oughly explore how HCMV impacts fatty acid biosynthesis
during the course of viral infection, we assayed fatty acid bio-
synthetic activity at numerous points throughout the HCMV
life cycle. As shown in Fig. 1A, HCMV-infected fibroblasts and
uninfected cells showed similar levels of fatty acid biosynthesis
at 24 hpi. However, at 48 hpi, there was a substantial increase
in fatty acid biosynthesis in HCMV-infected fibroblasts com-
pared to that in mock-infected fibroblasts, 6-fold (Fig. 1A).
This elevation in fatty acid biosynthetic activity continued to
increase at 72 hpi. The fatty acid biosynthetic increase occurs
after the bulk of viral immediate early gene expression has
occurred and corresponds to a time of rapid viral DNA repli-
cation and virion assembly, i.e., 48 to 72 hpi.
ACC catalyzes the first committed step of fatty acid biosyn-
thesis and is heavily regulated to control the rate of fatty acid
biosynthesis (reviewed in reference 9). The observation that
viral infection activates fatty acid biosynthesis raised the pos-
sibility that HCMV infection increases cellular ACC activity.
To test the impact of HCMV infection on ACC activity, we
utilized an in vitro LC–MS-MS–based ACC assay that mea-
sures the accumulation rate of malonyl-CoA, the product of
the reaction catalyzed by ACC. At various times postinfection,
we harvested mock- or HCMV-infected fibroblasts and ana-
lyzed the resulting lysates for ACC activity. At 24 hpi, there
was only a slight increase in ACC activity, but at 48 and 72 hpi,
there was a more substantial increase in ACC activity, a greater
than 5-fold increase (Fig. 1B). These results indicate that
HCMV infection increases cellular ACC activity upon infec-
tion at times that correspond to increased fatty acid biosyn-
thetic activity, consistent with ACC being a major regulator of
fatty acid biosynthesis (9).
HCMV infection induces an increase in ACC1 mRNA and
protein expression. Given the increase in fatty acid biosynthe-
sis and ACC activity observed during HCMV infection, we
hypothesized that the expression of lipogenic enzymes might
be upregulated by HCMV infection. To investigate this possi-
bility, we analyzed the mRNA transcript abundance of several
fatty acid biosynthetic enzymes via quantitative PCR. The en-
zymes analyzed included ACL, ACC1, ACC2, and FAS. While
the levels of ACL, ACC2, and FAS were elevated only mar-
ginally by HCMV infection compared to those for mock-in-
fected controls, the levels of ACC1 were increased more sub-
stantially, 3-fold (Fig. 2A). The accumulation of ACC1 over
ACC2 is consistent with the literature, as ACC1 is ubiquitously
expressed in numerous tissues, while the ACC2 isoform is
expressed primarily in highly metabolic/fatty acid oxidative tis-
sues, such as liver and muscle (33).
The results indicating HCMV-induced increases in ACC1
mRNA abundance suggested that HCMV may induce accu-
mulation of the ACC1 enzyme. To address this possibility, the
accumulation of ACC1 was analyzed over the course of viral
infection. ACC1 protein levels increased throughout HCMV
infection, starting at 24 hpi, and reached a maximal amount
compared to levels in mock-infected cells at 72 hpi (Fig. 2B).
Quantification of ACC1 levels, after normalization to tubulin
as a loading control, showed a greater than 2-fold and 3-fold
increase in HCMV-infected cells at 48 and 72 hpi, respectively,
FIG. 1. Impact of HCMV infection on fatty acid biosynthesis and
ACC activity. (A) Time course of fatty acid biosynthesis during HCMV
infection. Serum-starved MRC-5 fibroblasts were mock infected or
infected with HCMV (multiplicity of infection [MOI] of 3.0). Cells
were labeled with 14C-acetate at 24, 48, and 72 hpi for 2 h, at which
time lipids were extracted and saponified and the radioactivity in the
fatty acid fraction was scintillation counted. Values are means 
 stan-
dard errors (SE) (n  2). (B) Time course of ACC activity during
HCMV infection. Serum-starved MRC-5 fibroblasts were mock in-
fected or infected with HCMV (MOI of 3.0). Cells were harvested at
24, 48, and 72 hpi, and the ACC activity of the resulting cellular lysates
was measured via an LC–MS-MS–based ACC activity assay. ACC
activity data are from a representative experiment of four (means 

SE, n  2).
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compared to levels in mock-infected cells (Fig. 2C). In contrast
to the increases in ACC1 protein, the levels of ACL protein,
another enzyme involved in fatty acid biosynthesis, were not
affected by HCMV infection (Fig. 2B). The observed increases
in ACC1 mRNA and protein abundance indicate that HCMV
infection increases the expression of ACC1 and are consistent
with the increases in fatty acid biosynthesis and ACC1 activity
observed during HCMV infection.
HCMV gene expression but not viral DNA replication is
necessary for HCMV-induced increases in ACC1 abundance.
HCMV infection consists of a highly ordered program of viral
gene expression. However, prior to the expression of viral
genes, HCMV virion binding to cellular receptors results in the
activation of numerous signal transduction pathways (44, 45).
Furthermore, viral envelope fusion releases into the cytoplasm
numerous viral tegument proteins that engage in diverse ac-
tivities to initiate viral infection (5, 8, 25, 48). With these
considerations in mind, we utilized UV-irradiated virus to de-
termine whether viral binding/tegument protein delivery was
sufficient for induction of ACC1 accumulation or whether viral
gene expression was necessary. While UV irradiation is pref-
erentially absorbed by nucleic acids over proteins, at higher
doses proteins also become UV damaged. We therefore set out
to determine a dose that would inhibit viral gene expression
but not substantially impact viral tegument protein function. It
is impossible to control for every function of every tegument
protein, so we decided on an assay for pp65 transport to the
nucleus as an estimate for functional tegument protein activity.
The pp65 protein is an abundant tegument protein that upon
infection is released to the cytosol and traffics to the nucleus
(43). We empirically determined a UV dose that would atten-
uate HCMV viral gene expression but not impact pp65 nuclear
trafficking. As shown in Fig. 3A, UV-irradiating HCMV virions
with 480 or 240 mJ/cm2 did not impact the transport of pp65 to
the nuclei of infected cells. At these same dosages, the accu-
mulation of two viral genes, IE2 and UL26, was substantially
decreased (Fig. 3B). Furthermore, UV irradiation completely
blocked the HCMV-induced accumulation of ACC1 (Fig. 3B).
These results indicate that viral binding and tegument protein
FIG. 2. Impact of HCMV infection on ACC expression. (A) Abundance of fatty acid biosynthetic enzyme mRNA. Serum-starved MRC-5
fibroblasts were mock infected or infected with HCMV (MOI of 3.0). Cells were harvested at 48 hpi and analyzed by quantitative PCR. The
resulting data were normalized to GAPDH and plotted with respect to mock infection (means 
 SE, n  3). (B) Accumulation of fatty acid
biosynthetic enzymes during the course of HCMV infection. Serum-starved MRC-5 fibroblasts were mock infected (M) or infected with HCMV
(H) (MOI of 3.0). Cells were harvested for protein analysis at 4, 24, 48, and 72 hpi and processed for Western analysis using the indicated
antibodies. Data are from a representative experiment of four. (C) Quantification of ACC1 levels during HCMV infection. ACC1- and
-tubulin-specific signals were scanned by phosphorimager. The resulting HCMV ACC1 signal was normalized by its respective -tubulin signal
and plotted with respect to mock infection (means 
 SE, n  3).
FIG. 3. (A) Analysis of the delivery of pp65 upon infection with UV-irradiated virus. Serum-starved MRC-5 fibroblasts were infected with
HCMV (MOI of 3.0) that had been UV irradiated (254 nm) with 0, 240, or 480 mJ/cm2 prior to infection. Cells were fixed and processed for
immunofluorescence at 4 hpi using a pp65-specific monoclonal antibody (green). (B) Accumulation of ACC1 protein after infection with
UV-irradiated virus. Mock-infected (M) or HCMV-infected (H) cells were treated as described above and harvested for protein analysis at 72 hpi.
The abundance of ACC1, -tubulin, IE2, and UL26 was measured by Western analyses. (C) Accumulation of phosphorylated ACC1 and ACC1
protein after treatment with PAA. Serum-starved MRC-5 fibroblasts were mock infected or infected with HCMV (MOI of 3.0). After adsorption,
the cellular medium was removed and fresh medium containing 50 g/ml PAA was added. Cells were harvested for protein analysis at 72 hpi. The
abundance of phosphorylated ACC1, ACC1, and -tubulin was measured by Western analysis.
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delivery is not sufficient for induction of ACC1 levels, suggest-
ing that viral gene expression is required.
As we found that the induction of ACC1 levels started at
approximately 24 to 48 hpi and peaked at 72 hpi (Fig. 2B), we
were interested to determine if late gene expression was nec-
essary for ACC1 induction. Since abundant late gene expres-
sion depends on viral DNA synthesis, we sought to determine
whether viral DNA synthesis was necessary for induction of
ACC1 by treatment with PAA, which specifically inhibits viral
DNA replication (23). As shown in Fig. 3C, addition of 50
g/ml PAA at the time of adsorption did not block the HCMV-
induced accumulation of total ACC1. Treatment with PAA
also did not prevent the accumulation of phosphorylated
ACC1 (pACC1) (Fig. 3C), a process which is discussed below.
This result indicates that viral DNA synthesis is not required
for induction of ACC1 levels during HCMV infection, suggest-
ing that production of late proteins is not necessary for the
induction of ACC1 protein accumulation.
HCMV infection increases the specific activity of ACC.
HCMV-infected cell lysates possessed increased ACC activity
compared to mock-infected lysates (Fig. 1B). An increase in
ACC activity in cell lysates can result from an increased con-
centration of an enzyme or from an increase in the specific
activity of the enzyme. The observed increases in ACC1 pro-
tein levels during HCMV infection (Fig. 2B) likely contribute
to the increase in ACC activity in HCMV-infected cellular
lysates (Fig. 1B). To determine if HCMV infection increases
the specific activity of ACC, we performed in vitro ACC assays
that were normalized to the relative concentration of ACC1
protein present. At 72 hpi, the specific activity of ACC in
HCMV-infected cell lysates was approximately 3-fold higher
than that in mock-infected cell lysates (Fig. 4). These results
suggest that HCMV infection induces the specific activity of
ACC in addition to increasing its expression.
HCMV infection and the ser79 phosphorylation status of
ACC1. ACC1 specifically, and fatty acid biosynthesis conse-
quently, is negatively regulated by phosphorylation of ACC1 at
ser79 (20, 33). After finding that HCMV infection induces an
increase in ACC specific activity (Fig. 4), we hypothesized that
HCMV infection may result in decreased phosphorylation at
ser79. To examine this possibility, we analyzed HCMV-in-
fected cells at various times postinfection utilizing an ACC
phospho-ser79-specific antibody. Surprisingly, HCMV infec-
tion induced an increase in the amount of ser79-phosphory-
lated ACC (Fig. 5A). Given the similarities between the in-
crease in ACC1 abundance and the increase in phospho-ser79
abundance (Fig. 2 and 5), we wanted to confirm that the
phospho-ACC-specific antibody was indeed specific for phos-
phorylated ACC. To address this issue, we utilized calf intes-
FIG. 4. Impact of HCMV infection on ACC specific activity. Se-
rum-starved MRC-5 fibroblasts were mock infected or infected with
HCMV (MOI of 3.0). Cells were harvested at 72 hpi, and the ACC
activity of the resulting cellular lysates was measured and normalized
by the relative concentration of ACC1 protein (means 
 SE, n  3).
FIG. 5. (A) Accumulation of phosphorylated ACC1 over the
course of HCMV infection. Serum-starved MRC-5 fibroblasts were
mock infected (M) or infected with HCMV (H) (MOI of 3.0). Cells
were harvested for protein analysis at 4, 24, 48, and 72 hpi. The
abundance of phosphorylated ACC1, ACC1, and -tubulin was mea-
sured by Western analysis. Data are from a representative experiment
of four. (B) Quantification of total phosphorylated ACC1 during
HCMV infection. Phosphorylated-ACC1- and -tubulin-specific West-
ern signals were scanned by phosphorimager. The resulting HCMV
phosphorylated ACC1 signal was normalized by its respective -tubu-
lin signal and plotted with respect to mock infection (means 
 SE, n 
3). (C) Quantification of phosphorylated ACC1 relative to total ACC1
during HCMV infection. Phosphorylated-ACC1-, ACC1-, and -tubu-
lin-specific Western signals were scanned by phosphorimager. The
resulting HCMV phosphorylated ACC1 and ACC1 signals were nor-
malized by their respective -tubulin signals. Phosphorylated ACC1
was subsequently normalized to ACC1 and plotted with respect to
mock infection (means 
 SE, n  3). (D) Serum-starved MRC-5
fibroblasts were mock infected or infected with HCMV (MOI of 3.0).
Cells were harvested at 72 hpi and immediately treated with calf
intestinal phosphatase (CIP). After CIP treatment, the abundance of
phosphorylated ACC1, ACC1, and -tubulin was measured by West-
ern analyses.
5818 SPENCER ET AL. J. VIROL.
tinal phosphatase (CIP) to determine if the pACC1-specific
signal was phosphatase sensitive. As shown in Fig. 5D, phos-
phorylated ACC1 was not detectable in lysates treated with
CIP, in contrast to results with non-CIP-treated lysates. Total
ACC1 was still detectable regardless of CIP treatment. These
results indicate that the phospho-ACC-specific antibody is spe-
cific for phosphorylated ACC. To examine the increases in
pACC1 more closely, we utilized a phosphorimager to quantify
the increases in total pACC1, i.e., after normalizing the pACC
signal by the tubulin signal (Fig. 5B), as well as to quantify the
relative ratio of pACC1/ACC1, i.e., after normalizing the
pACC1 signal by the total ACC1 signal (Fig. 5C). HCMV
infection increased the total amount of ser79 ACC1 phosphor-
ylation starting at 4 hpi (Fig. 5B) and continuing throughout
the time course, peaking with an approximate 3-fold increase
at 72 hpi (Fig. 5B). Analysis of the ratio of pACC1/ACC1
suggests an increase in pACC1 relative to total ACC1 at 4 hpi
in HCMV-infected cells (Fig. 5C). However, at later time
points the HCMV-mediated increase in ser79 pACC1 is equiv-
alent to the HCMV-mediated increase in total ACC1, with the
ratio of pACC1 to total ACC1 not changing (Fig. 5C). Our
results indicate that while the total amount of ser79 pACC is
increased during HCMV infection, the relative proportion of
pACC remains largely unchanged. These results indicate that
HCMV infection does not mediate ACC1 activation through a
reduction of ser79 ACC1 phosphorylation.
Analysis of ACC1 localization. ACC1 is typically located in
the cellular cytoplasm (19). As HCMV infection frequently
targets the localization of numerous cellular proteins, we
sought to determine how HCMV infection might impact the
localization of ACC1. Of particular note in the analysis of
ACC1 localization was the importance of using human serum
in the confocal blocking buffer, the absence of which resulted
in localization artifacts likely due to the presence of HCMV-
encoded Fc receptors (see Materials and Methods; also see
Fig. S1 in the supplemental material). Utilizing confocal mi-
croscopy, we found ACC1 to be localized to the cytoplasm
during mock infection (Fig. 6). During HCMV infection,
ACC1 was also primarily cytoplasmic at all time points tested
(Fig. 6). While the localization of ACC did not change during
the course of HCMV infection, the fluorescent intensity of
ACC1-specific signal (utilizing identical confocal settings) was
increased at 48 and 72 hpi compared to that for mock-infected
cells (Fig. 6), consistent with our previous data indicating an
increase in ACC1 expression.
Impact of ACC1 inhibition at various times postinfection.
We have previously reported that pharmaceutical inhibition of
various fatty acid biosynthetic enzymes attenuates HCMV rep-
lication without affecting the accumulation of selected viral
proteins representative of all three stages of viral gene expres-
sion, i.e., immediate early, early, and late (35). These results
suggested that inhibition of fatty acid biosynthesis attenuates
viral replication at a late stage of infection. If ACC1 activity is
required at the later stages of infection, addition of an ACC1
inhibitor at later points of infection should still attenuate viral
replication. To test this possibility, we employed TOFA, an
ACC inhibitor (27). As shown in Fig. 7, addition of 5 g/ml or
10 g/ml of TOFA at the time of adsorption resulted in a
greater than 10-fold or 100-fold attenuation of viral replica-
tion, respectively. TOFA treatment at 24 hpi still resulted in a
greater than 10-fold reduction with addition of 5 g/ml TOFA
and 100-fold reduction with addition of 10 g/ml TOFA (Fig.
7A). Addition of 5 g/ml TOFA at 48 hpi, a time point where
fatty acid biosynthesis is already substantially induced by in-
fection (Fig. 1A), resulted in an attenuation of viral growth
(10-fold) similar to that seen with TOFA treatment at earlier
time points (Fig. 7A). Addition of 10 g/ml TOFA at 48 hpi
also attenuated viral growth more than 10-fold, still a substan-
tial reduction but a smaller inhibitory effect than when TOFA
was added at earlier times postinfection (Fig. 7A). Addition of
5 or 10 g/ml TOFA at 72 hpi had no inhibitory effect on viral
growth (Fig. 7A). The attenuation of viral production induced
by addition of TOFA at later time points, i.e., 24 and 48 hpi,
suggests that TOFA works at later times of infection, consis-
tent with a role in late viral processes, such as envelopment.
That treatment of cells with TOFA at 72 hpi does not impact
production of HCMV virions suggests that TOFA does not
attenuate infectious virions by binding or interfering with the
activity of newly formed enveloped virions. It does, however,
suggest that the window of sensitivity to fatty acid biosynthetic
inhibition closes prior to 72 hpi.
To gauge the impact of TOFA treatment on virally induced
fatty acid biosynthesis, we treated HCMV-infected cells with
DMSO or 5 or 10 g/ml TOFA and assayed for fatty acid
biosynthesis. As expected, treatment of HCMV-infected cells
with increasing concentrations of TOFA resulted in a dose-
dependent reduction in fatty acid biosynthesis (Fig. 7B). To
analyze how TOFA treatment impacts the cellular viability of
mock- or HCMV-infected cells, we treated cells with 10 g/ml
TOFA and assayed for cell viability utilizing the Live/Dead
assay, which stains live cells based on a their esterase activity
(green) and stains the nucleic acids of dead cells based on the
breakdown of membrane integrity (red). As shown in Fig. 7C,
treatment of mock-infected or HCMV-infected cells with 10
g/ml TOFA did not induce cellular toxicity, as made evident
by the vast majority of cells staining green (95%) versus red
FIG. 6. Time course of ACC1 localization. Serum-starved MRC-5
fibroblasts were mock infected or infected with HCMV (MOI of 3.0).
Cells were fixed and processed for confocal immunofluorescence anal-
ysis at 24, 48, and 72 hpi using an ACC1-specific antibody (green).
DNA was stained with DAPI (blue). All fields were captured with
identical confocal settings.
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(	5%). These results suggest that TOFA treatment inhibits
fatty acid biosynthesis and does not induce cellular toxicity.
Analysis of SREBP-2 processing and mTOR’s contribution
to HCMV-induced ACC1 expression and fatty acid biosynthe-
sis. Our results indicate that HCMV infection induces the
levels of ACC1 mRNA and protein (Fig. 2). One potential
mechanism behind this increase in ACC1 mRNA levels is
transcriptional activation. Many cholesterol and fatty acid bio-
synthetic genes, including ACC1, contain sterol response ele-
ments (SRE) in their promoters which are activated upon
binding by sterol regulatory element binding proteins
(SREBPs) (reviewed in reference 6). Members of this family,
e.g., SREBP-2, are endoplasmic reticulum (ER)-resident pro-
teins that are transcriptionally inactive unless proteolytically
cleaved, resulting in N-terminal translocation to the nucleus,
whereupon they can activate SRE-containing genes (22, 41).
To test whether HCMV infection activates the processing of
SREBP-2, we employed an antibody that recognizes both the
full-length SREBP-2 precursor (125 kDa) and the activated/
cleaved N-terminal fragment (65 kDa) (50). Mock- and
HCMV-infected cells were analyzed at various times postin-
fection for the accumulation of both the full-length SREBP-2
precursor and its N-terminal proteolytic fragment by using two
independently derived antibodies directed against SREBP-2, a
mouse monoclonal and a rabbit polyclonal antibody. As shown
in Fig. 8A, Western blot analysis with the polyclonal antibody
indicated a band of approximately 65 kDa, a size consistent
with the N-terminal proteolytic fragment, that was present
specifically during HCMV infection at 24, 48, and 72 hpi.
Western analysis utilizing a monoclonal antibody directed
against SREBP-2 also demonstrated an identically sized
HCMV-specific band consistent with SREBP-2 processing;
however, this band was absent at 24 hpi, present at 48 hpi, and
greatly diminished but detectable at 72 hpi (Fig. 8B). HCMV
infection did not appreciably impact the accumulation of full-
length SREBP-2 (Fig. 8); however, Western analysis with the
polyclonal antibody indicated the potential presence of a full-
length SREBP-2 doublet specifically in HCMV-infected lanes
FIG. 7. (A) Growth characteristics of HCMV in cells treated with TOFA. Confluent MRC-5 fibroblasts were mock infected or infected with
HCMV-GFP (MOI of 3.0). After adsorption, free virus was sodium citrate inactivated. At various times, as indicated, the cellular medium was
removed and fresh medium with DMSO or TOFA was added. For all applicable cultures, at 48 hpi, the medium was changed, and fresh medium
containing DMSO or TOFA was added. At 96 hpi, cells were harvested and viral titers were determined via standard plaque assay (means 
 SE,
n  4). (B) Analysis of the impact of TOFA treatment on fatty acid biosynthesis during HCMV infection. Confluent MRC-5 fibroblasts were
infected with HCMV (MOI of 3.0). After a 2-h adsorption period, the inoculum was aspirated and fresh medium containing DMSO or the
indicated TOFA dose was added. At 48 hpi, the medium was changed, and fresh DMSO or TOFA was added. Cells were labeled with 14C-acetate
at 72 hpi for 2 h. Lipids were extracted and saponified, and the radioactivity in the fatty acid fraction was scintillation counted. Values are means 

SE (n  2). (C) Analysis of the potential cytotoxicity associated with TOFA treatment. Confluent MRC-5 fibroblasts were mock infected or
infected with HCMV (MOI of 3.0). After a 2-h adsorption period, the inoculum was aspirated and fresh medium containing 10 g/ml TOFA was
added. At 48 hpi, the medium was changed, and fresh TOFA was added. At 72 hpi, cell viability was measured via a Live/Dead cell viability assay
according to the manufacturer’s instructions (MGT). Green indicates the presence of esterase activity, associated with viable cells, while red
indicates a loss of cellular membrane integrity, associated with cell death. As a positive control for staining of a breakdown in membrane integrity,
cells were treated with ethanol (
 Control). The images were obtained by inverted fluorescence microscopy.
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(Fig. 8A). This could be indicative of a posttranslational mod-
ification of the full-length protein. This doublet, however, was
not detected in the extracts assayed with the monoclonal an-
tibody (Fig. 8B). Taken together, the combined results using
both antibodies suggest that HCMV induces proteolytic pro-
cessing of SREBP-2, which is consistent with transcriptional
activation of SRE-containing genes, including ACC1.
The mammalian target of rapamycin (mTOR) has been
linked to SREBP expression and proteolytic processing (14,
40). In addition, mTOR activity is important for expression of
fatty acid biosynthetic enzymes and fatty acid biosynthesis (14),
as well as for HCMV infection (12, 32). We hypothesized that
mTOR activity may be required for HCMV-induced SREBP-2
processing. Furthermore, if SREBP-2 processing is required
for HCMV-mediated induction of ACC1 expression, inhibition
of mTOR is predicted to block the HCMV-mediated induction
of ACC1 expression. To test this possibility, we employed
Torin1, an mTOR inhibitor (47). To gauge the impact of
mTOR inhibition on virally induced SREBP-2 as well as ACC1
expression, we treated mock- and HCMV-infected cells with
DMSO or 250 nM Torin1 and assayed for SREBP-2 processing
and ACC1 expression via Western analysis. Treatment of
HCMV-infected cells with Torin1 resulted in a reduction in
full-length SREBP-2 expression and complete ablation of
SREBP-2 processing (Fig. 8C). Furthermore, Torin1 treat-
ment blocked HCMV-induced ACC1 expression at both 48
and 72 hpi (Fig. 8C). These results are consistent with a sce-
nario in which mTOR-dependent SREBP-2 processing is im-
portant for HCMV-mediated induction of ACC1 expression.
To determine the impact of mTOR inhibition on virally in-
duced fatty acid biosynthesis, we again treated mock- and
HCMV-infected cells with DMSO or 250 nM Torin1 and as-
sayed for fatty acid biosynthesis. As shown in Fig. 8D, Torin1
treatment completely abrogated the induction of fatty acid
biosynthesis observed upon HCMV infection. Taken together,
these results suggest that mTOR activity is necessary for
HCMV-mediated SREBP-2 processing, induction of ACC1
expression, and activation of fatty acid biosynthesis.
Analysis of the impact of ACC1 siRNA treatment during
HCMV infection. To further explore the role of ACC1 during
HCMV infection, we utilized RNAi to target ACC1 expression
levels. ACC1 siRNA treatment resulted in an approximately
32% reduction in ACC1 expression in both mock- and HCMV-
infected cells compared to that seen with a control siRNA (Fig.
9A). Fatty acid biosynthesis was also measured following
siRNA-mediated knockdown of ACC1. ACC1 knockdown re-
sulted in a reduction in fatty acid biosynthesis in both mock-
and HCMV-infected cells (Fig. 9B). While the impact of
ACC1-specific RNAi on ACC1 protein levels was modest (Fig.
9A), we were interested to determine if RNAi-mediated tar-
geting of ACC1 would impact HCMV replication. As shown in
Fig. 9C, treatment with an ACC1-specific siRNA resulted in
significant reduction in viral replication, 10-fold. These re-
sults further support the importance of ACC1 for production
of wild-type levels of HCMV progeny.
DISCUSSION
Viruses are entirely dependent on their host cells to provide
the energy and biomass necessary for the production of viral
particles. However, the mechanisms through which viruses en-
sure that their metabolic needs are met are mostly unclear. We
find that HCMV targets multiple facets of a central regulator
of fatty acid biosynthesis, ACC1. Our results indicate that
HCMV infection increases the abundance of ACC1 mRNA
and protein (Fig. 2). Our data show that viral binding and
tegument protein delivery is not sufficient for the induction of
ACC1 protein levels (Fig. 3). This result suggests that expres-
FIG. 8. Accumulation of SREBP-2 over time during HCMV infection. (A and B) Serum-starved MRC-5 fibroblasts were mock infected (M) or
infected with HCMV (H) (MOI of 3.0). Cells were harvested for protein analysis at 24, 48, and 72 hpi. The abundance of SREBP-2 was measured
by Western analyses using a rabbit polyclonal antibody (A) or a mouse monoclonal antibody (B). -Tubulin was also blotted as a loading control.
Western data for each antibody are from a representative experiment of two. (C) Analysis of the impact of Torin1 treatment on SREBP-2 and
ACC1 accumulation over time during HCMV infection. Serum-starved MRC-5 fibroblasts were mock infected (M) or infected with HCMV
(H) (MOI of 3.0). After a 2-h adsorption period, the inoculum was aspirated and fresh medium containing DMSO or 250 nM Torin1 was added.
Cells were harvested for protein analysis at 48 and 72 hpi. The abundance of SREBP-2, ACC1, and -tubulin was measured by Western analysis.
(D) Analysis of the impact of Torin1 treatment on fatty acid biosynthesis during HCMV infection. Confluent MRC-5 fibroblasts were infected with
HCMV (MOI of 3.0). After a 2-h adsorption period, the inoculum was aspirated and fresh medium containing DMSO or 250 nM Torin1 was
added. At 48 hpi, the medium was changed, with fresh DMSO or 250 nM Torin1 added. Cells were labeled with 14C-acetate at 72 hpi for 2 h. Lipids
were extracted and saponified, and the radioactivity in the fatty acid fraction was scintillation counted.
VOL. 85, 2011 HCMV ACTIVATION OF ACC1 5821
sion of a downstream viral gene(s) is required for increased
ACC1 levels. Additionally, we find that viral DNA replication
is not necessary for increased ACC1 levels, suggesting that true
late gene expression is not necessary for induction of ACC1
levels. While our results argue that this induction of ACC1
expression is dependent on viral protein synthesis but not on
viral DNA replication, the exact viral mechanisms responsible
for these increases require further investigation. We also find
that HCMV infection results in the proteolytic activation of
SREBP-2, a known transcriptional activator of phospholipid
metabolic genes containing SRE promoter elements (such as
ACC1). SREBP-2 processing and ACC1 expression are both
simultaneously blocked by pharmaceutical inhibition of mTOR
(Fig. 8), a known SREBP activator (14). Taken together, these
results are consistent with a scenario in which HCMV tran-
scriptionally activates ACC1 through increased SREBP-2 pro-
cessing, resulting in binding and activation of the ACC1 pro-
moter. With respect to the dependence of ACC1 expression on
mTOR activity, given mTOR’s well-established role in trans-
lational regulation, we cannot rule out a potential impact of
mTOR inhibition on ACC1 translation. Further experiments
analyzing SREBP-2 occupancy at the ACC1 promoter and its
impact on ACC1 promoter activity will provide insight into
SREBP-2’s role in the activation of ACC1 expression.
The inhibitory effect of Torin1 treatment on HCMV infec-
tion could in part reflect the inhibition of fatty acid biosynthe-
sis observed upon Torin1 treatment. However, Torin1 treat-
ment has an additional effect on DNA replication and viral
gene synthesis that is not observed upon pharmaceutical inhi-
bition of ACC (12, 32, 35). This suggests that there are other
additional roles for mTOR during HCMV replication.
HCMV infection also resulted in an increase in the specific
activity of ACC1 (Fig. 4). As ACC activity is negatively regu-
lated by phosphorylation, we hypothesized that ACC would be
dephosphorylated at ser79 during HCMV infection. On the
contrary, we find that the total amount of ser79-phosphory-
lated ACC increased during infection, concurrent with in-
creases in total ACC, resulting in similar ratios of ser79 phos-
pho-ACC to total ACC in infected and uninfected cells (Fig.
5). These results suggest that dephosphorylation of ACC1
ser79 is not the mechanism through which HCMV activates
ACC specific activity. The increase in ACC enzymatic activity
observed during HCMV infection could be the result of an
increase in the activity of ser79-phosphorylated ACC, non-
phosphorylated ACC, or both. One possibility is that HCMV
infection induces association with viral or cellular factors re-
sulting in its activation. Various ACC-associated cellular reg-
ulators have been reported previously (reviewed in reference
9). Another possibility for activation of cellular ACC is through
increasing the concentrations of an allosteric activator, such as
citrate (20, 46). We have previously found that HCMV infec-
tion increases the concentrations of citrate substantially (34,
35), which is predicted to result in cellular ACC activation.
However, increases in cellular citrate concentrations do not
completely explain the in vitro activity differences we observe,
as citrate is a necessary component of the activity assay. Other
studies have suggested that ACC multimerization is correlated
with ACC activity (31), which could be affected by HCMV
infection. Further experimentation with respect to the impact
of HCMV infection on the activity of phosphorylated and
FIG. 9. Analysis of the impact of ACC1 siRNA treatment on ACC1
expression, fatty acid biosynthesis, and viral growth during HCMV
infection. (A) MRC-5 fibroblasts at 30% confluence were transfected
with 75 nM siRNA oligonucleotides specific for ACC1 and an unspe-
cific control (Neg). At 24 h posttransfection, the cells were serum
starved, and 24 h later, cells were mock infected (M) or infected with
HCMV (H) (MOI of 3.0). Cells were harvested for protein analysis at
72 hpi, and the abundance of ACC1 and -tubulin was measured by
Western analysis. Data are from a representative experiment of two.
(B) Cells were labeled with 14C-acetate at 72 hpi for 2 h, at which time
lipids were extracted and saponified and the radioactivity in the fatty
acid fraction was scintillation counted. Values are means 
 SE (n  2).
(C) After adsorption, free virus was sodium citrate inactivated. At 72
hpi, cells were harvested and viral titers were determined via standard
plaque assay (means 
 SE, n  2).
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dephosphorylated ACC as well as ACC multimerization will
likely provide insights into how HCMV induces the activity of
this protein.
Most of our experiments were performed in serum-starved
cells. We would argue that in many cases HCMV infects qui-
escent cells that are not actively growing. If so, infection of
quiescent, serum-starved cells would reflect this possibility bet-
ter than infection of rapidly growing cells stimulated with fetal
growth factors. Regardless, we find that HCMV infection in
the presence of serum still induces fatty acid biosynthesis,
albeit to a lesser extent, and that pharmaceutical inhibition of
ACC inhibits HCMV growth regardless of the presence of
serum (data not shown), suggesting that these phenotypes are
not dependent on serum starvation.
One unanswered question is how inhibition of fatty acid
biosynthesis attenuates HCMV replication. Our data suggest
that fatty acid biosynthesis is required at a relatively late stage
during infection (Fig. 7). The simplest explanation is that fatty
acid biosynthesis is necessary for the bulk production of fatty
acids required for viral envelope phospholipids and that inhi-
bition of this pathway limits the production of viral envelope.
A related, but slightly different scenario is that the viral enve-
lope consists of specific phospholipids whose production is
activated and important for production of infectious virions. If
this were the case, specific phospholipid-modifying enzymes
working downstream of ACC1 would be potential targets for
antiviral therapy. To our knowledge, no one has reported a
detailed biochemical analysis of the HCMV phospholipid en-
velope, which would identify the relevant lipid species and
thereby illuminate phospholipid metabolic enzymes of interest.
An alternative possibility is that HCMV replication depends
on fatty acid biosynthesis for the modification of specific pro-
teins. Fatty acid-based protein modifications, for example, my-
ristoylation, are often essential for protein localization and
function. This could be the case for the HCMV pp28 protein,
an essential protein whose myristoylation is necessary for its
proper localization and incorporation into virions (24, 51).
Whether fatty acid biosynthesis is required for production of
phospholipids or fatty acid protein modifications, its require-
ment at late times postinfection suggests that HCMV targeting
of ACC1 is important for virion assembly and production. It is
clear that HCMV infection targets this regulatory enzyme in
multiple ways, and future work will elucidate the specific mech-
anisms involved and identify the specific fatty acid biosynthetic
requirements for HCMV replication.
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